Literature DB >> 32096030

Tau and Axonal Transport Misregulation in Tauopathies.

Benjamin Combs1, Rebecca L Mueller1,2, Gerardo Morfini3,4, Scott T Brady3,4, Nicholas M Kanaan5,6,7.   

Abstract

Tau is a microtubule-associated protein that is involved in both normal and pathological processes in neurons. Since the discovery and characterization of tau over 40 years ago, our understanding of tau's normal functions and toxic roles in neurodegenerative tauopathies has continued to expand. Fast axonal transport is a critical process for maintaining axons and functioning synapses, critical subcellular compartments underlying neuronal connectivity. Signs of fast axonal transport disruption are pervasive in Alzheimer's disease and other tauopathies and various mechanisms have been proposed for regulation of fast axonal transport by tau. Post-translational modifications of tau including phosphorylation at specific sites, FTDP-17 point mutations, and oligomerization, confer upon tau a toxic effect on fast axonal transport. Consistent with the well-established dependence of axons on fast axonal transport, these disease-related modifications are closely associated temporally and spatially with axonal degeneration in the early disease stages. These factors position tau as a potentially critical factor mediating the disruption of fast axonal transport that precedes synaptic dysfunction and axonal degeneration at later disease stages. In this chapter, we review the evidence that tau affects fast axonal transport and examine several potential mechanisms proposed to underlie this toxicity.

Entities:  

Keywords:  Alzheimer’s disease; Axonal transport; Axons; Kinases; Neurodegeneration; Phosphatases; Tau protein; Tauopathies

Year:  2019        PMID: 32096030      PMCID: PMC7099581          DOI: 10.1007/978-981-32-9358-8_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  111 in total

1.  Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.

Authors:  A Sengupta; J Kabat; M Novak; Q Wu; I Grundke-Iqbal; K Iqbal
Journal:  Arch Biochem Biophys       Date:  1998-09-15       Impact factor: 4.013

2.  Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of tauopathy.

Authors:  Megan A Sealey; Ergina Vourkou; Catherine M Cowan; Torsten Bossing; Shmma Quraishe; Sofia Grammenoudi; Efthimios M C Skoulakis; Amritpal Mudher
Journal:  Neurobiol Dis       Date:  2017-05-11       Impact factor: 5.996

3.  Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.

Authors:  Nicholas M Kanaan; Gerardo Morfini; Gustavo Pigino; Nichole E LaPointe; Athena Andreadis; Yuyu Song; Ellen Leitman; Lester I Binder; Scott T Brady
Journal:  Neurobiol Aging       Date:  2011-07-27       Impact factor: 4.673

4.  Tau reduction prevents Abeta-induced defects in axonal transport.

Authors:  Keith A Vossel; Kai Zhang; Jens Brodbeck; Aaron C Daub; Punita Sharma; Steven Finkbeiner; Bianxiao Cui; Lennart Mucke
Journal:  Science       Date:  2010-09-09       Impact factor: 47.728

5.  Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy.

Authors:  Zeshan Ahmed; Keith A Josephs; John Gonzalez; Anthony DelleDonne; Dennis W Dickson
Journal:  Brain       Date:  2007-12-24       Impact factor: 13.501

Review 6.  Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury.

Authors:  Ann C McKee; Robert C Cantu; Christopher J Nowinski; E Tessa Hedley-Whyte; Brandon E Gavett; Andrew E Budson; Veronica E Santini; Hyo-Soon Lee; Caroline A Kubilus; Robert A Stern
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

7.  Partial deletion of the MAPT gene: a novel mechanism of FTDP-17.

Authors:  Anne Rovelet-Lecrux; Magalie Lecourtois; Catherine Thomas-Anterion; Isabelle Le Ber; Alexis Brice; Thierry Frebourg; Didier Hannequin; Dominique Campion
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

8.  Kinesin-II is required for axonal transport of choline acetyltransferase in Drosophila.

Authors:  K Ray; S E Perez; Z Yang; J Xu; B W Ritchings; H Steller; L S Goldstein
Journal:  J Cell Biol       Date:  1999-11-01       Impact factor: 10.539

Review 9.  Axonal transport of the cytoplasmic matrix.

Authors:  R J Lasek; J A Garner; S T Brady
Journal:  J Cell Biol       Date:  1984-07       Impact factor: 10.539

10.  Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport.

Authors:  Victoria J Butler; Dominique A Salazar; David Soriano-Castell; Miguel Alves-Ferreira; Frank J A Dennissen; Mihir Vohra; Juan A Oses-Prieto; Kathy H Li; Austin L Wang; Beibei Jing; Biao Li; Alex Groisman; Edgar Gutierrez; Sean Mooney; Alma L Burlingame; Kaveh Ashrafi; Eva-Maria Mandelkow; Sandra E Encalada; Aimee W Kao
Journal:  Hum Mol Genet       Date:  2019-05-01       Impact factor: 6.150

View more
  18 in total

1.  Tau is not necessary for amyloid-β-induced synaptic and memory impairments.

Authors:  Daniela Puzzo; Elentina K Argyrousi; Agnieszka Staniszewski; Hong Zhang; Elisa Calcagno; Elisa Zuccarello; Erica Acquarone; Mauro Fa'; Domenica D Li Puma; Claudio Grassi; Luciano D'Adamio; Nicholas M Kanaan; Paul E Fraser; Ottavio Arancio
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

2.  Neuronal and Glial Distribution of Tau Protein in the Adult Rat and Monkey.

Authors:  Nicholas M Kanaan; Tessa Grabinski
Journal:  Front Mol Neurosci       Date:  2021-04-27       Impact factor: 5.639

3.  Liquid-liquid phase separation induces pathogenic tau conformations in vitro.

Authors:  Nicholas M Kanaan; Chelsey Hamel; Tessa Grabinski; Benjamin Combs
Journal:  Nat Commun       Date:  2020-06-04       Impact factor: 14.919

Review 4.  Cellular Biology of Tau Diversity and Pathogenic Conformers.

Authors:  Sang-Gyun Kang; Ghazaleh Eskandari-Sedighi; Lenka Hromadkova; Jiri G Safar; David Westaway
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

Review 5.  Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core.

Authors:  Elena Vacchi; Alain Kaelin-Lang; Giorgia Melli
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 6.  Tau Oligomers Neurotoxicity.

Authors:  Grazyna Niewiadomska; Wiktor Niewiadomski; Marta Steczkowska; Anna Gasiorowska
Journal:  Life (Basel)       Date:  2021-01-06

Review 7.  New Insights Into Drug Discovery Targeting Tau Protein.

Authors:  Yoshiyuki Soeda; Akihiko Takashima
Journal:  Front Mol Neurosci       Date:  2020-12-03       Impact factor: 5.639

8.  GSK3β Impairs KIF1A Transport in a Cellular Model of Alzheimer's Disease but Does Not Regulate Motor Motility at S402.

Authors:  K J Gan; A Akram; T L Blasius; E M Ramser; B G Budaitis; D R Gabrych; K J Verhey; M A Silverman
Journal:  eNeuro       Date:  2020-11-05

Review 9.  Selective Neuron Vulnerability in Common and Rare Diseases-Mitochondria in the Focus.

Authors:  Thomas Paß; Rudolf J Wiesner; David Pla-Martín
Journal:  Front Mol Biosci       Date:  2021-06-30

10.  Alleviation of depression-like behavior in a cystic fibrosis mouse model by Hdac6 depletion.

Authors:  Deborah A Corey; Sharon M Rymut; Thomas J Kelley
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.